Bacteriostatic saline for neurotoxin reconstitution is one of the most widely practised off-label choices in aesthetic medicine, and one of the least well explained. Dr. Chris Croley, Chief Medical Officer at Empire Medical Training, describes the practice in Empire's reconstitution curriculum in the careful terms it deserves:
"What's on label is normal saline, preservative free. Many of us will use bacteriostatic saline. That bacteriostatic saline has a preservative in it. It's called benzyl alcohol. And that gives us a little bit of a numbing, or helps the patients tolerate — there's less discomfort with the procedure. The preservative, to the best of our knowledge, doesn't change the performance of the toxin at all. And this has been used commonly in practices throughout the US and abroad."
That hedge — "to the best of our knowledge" — is the right posture, and it is also answerable. There is a published literature here, including randomised comparisons, and it supports most of what Croley describes while clarifying exactly what is and is not established.
What is in the bottle
Bacteriostatic 0.9% Sodium Chloride Injection, USP is a multiple-dose preparation in which each millilitre contains 9 mg of sodium chloride and 9 mg of benzyl alcohol — 0.9% benzyl alcohol — added as a bacteriostatic preservative. Its label pH is 5.0, with a specification range of 4.5 to 7.0. It is supplied in 10 mL, 20 mL and 30 mL multiple-dose vials, and the vial carton carries the warning NOT FOR USE IN NEONATES. FOR DRUG DILUENT USE ONLY.
Preservative-free 0.9% Sodium Chloride Injection, USP is the same isotonic sodium chloride solution without the benzyl alcohol, and is supplied as a single-dose preparation.
That difference — one preservative molecule at 9 mg/mL — produces every behavioural difference between the two products: the local anaesthetic effect, the bacteriostatic property that permits repeated entry into the vial, the neonatal contraindication, and the entire discussion below.
The regulatory position, stated plainly
Every botulinum toxin type A product approved in the United States names preservative-free 0.9% Sodium Chloride Injection, USP as its diluent. BOTOX Cosmetic's label goes further, specifying "Preservative-free 0.9% Sodium Chloride Injection, USP Only." DYSPORT, XEOMIN, JEUVEAU and DAXXIFY all specify the same preservative-free diluent.
Reconstituting with bacteriostatic saline is therefore an off-label act. That is a legitimate exercise of clinical judgement by a licensed prescriber, made constantly across medicine, and it is not the same thing as an unstudied one. But it should be a decision the clinician has made rather than one the practice drifted into, and it should be recorded.
What benzyl alcohol does to injection pain — the evidence
The comfort claim is the best-supported part of the picture.
Alam, Dover and Arndt, Archives of Dermatology, 2002. A two-arm study: a retrospective series of 20 consecutive patients, and a double-blind randomised split-face trial in 15 consecutive patients treated for upper-face dynamic lines, with one side receiving toxin reconstituted in preservative-containing saline and the other in preservative-free saline. In the retrospective arm, 18 of 20 patients reported the preserved-saline treatment less painful than their most recent prior treatment. In the randomised arm, 15 of 15 patients reported less pain on the preserved side (p<0.001), with pain scores 54% lower. The investigators reported no difference in treatment efficacy between sides, observed either by the investigators or by the patients.
Zidan and colleagues, International Journal of Clinical Practice, 2020 (B-RECON). A randomised, double-blind trial in 68 chronic migraine patients receiving onabotulinumtoxinA reconstituted with preserved or preservative-free saline. Procedure pain scores were significantly higher with preservative-free saline (5.3 versus 3.2). There was no difference in headache or migraine frequency in the immediate post-procedural period. This matters because it moves the finding out of aesthetics and into a population with scalp allodynia, where injection pain is both worse and clinically consequential.
Hunt and Malhotra, Eye, 2022. A review of the preserved-saline literature identifying 62 published studies on the subject since 1928, of which five reported significantly lower injection-associated pain for periocular and facial botulinum toxin injections reconstituted with preserved rather than preservative-free saline. The review also noted very low infection rates after periocular botulinum toxin injection and described benzyl-alcohol preserved saline as inexpensive, with minimal reported complications, particularly in periocular administration.
The mechanism is unremarkable: benzyl alcohol is a weak local anaesthetic in its own right, long used to reduce the sting of injected solutions. At 0.9% it is well below the concentrations studied as a standalone anaesthetic, which is consistent with a modest but reproducible reduction in injection discomfort rather than true anaesthesia.
What benzyl alcohol does to the toxin — what is and is not established
This is where Croley's hedge earns its place, and where the honest answer is more nuanced than either camp usually allows.
No efficacy difference was detected in the trials that looked. The Alam split-face study, which is the most directly relevant design available, reported no observed difference in treatment efficacy between the preserved and preservative-free sides. That is a real finding from a real trial, but it is a small trial designed and powered around pain, not efficacy, and absence of a detected difference in 15 patients is not proof of equivalence.
Direct stability data exists for one product. Ellis, Thach and Gallagher published stability and microbial-control data in Toxins in 2023 on reconstituted daxibotulinumtoxinA, testing 50 Unit and 100 Unit vials reconstituted with either unpreserved or preserved saline and stored refrigerated at 2°C to 8°C. pH and biological activity remained stable at the final assessed time point in both diluents, no change in recoverable 150 kDa neurotoxin was observed by ELISA over six days of refrigeration, and no bacterial growth or pathogen proliferation was observed in either preparation. It is a manufacturer-authored study on a single product, which is a limitation worth naming, but it is direct biochemical evidence rather than inference.
A well-publicised claim in the opposite direction does not hold up. Anecdotal reports have circulated suggesting that injecting bacteriostatic saline can reverse toxin-induced brow ptosis. Rahman and colleagues examined the hypothesis in Toxins in 2025 using pharmacokinetic/pharmacodynamic modelling across 30,000 simulated patients, and concluded that bacteriostatic saline does not reverse the molecular action of botulinum toxin. In their model, benzyl alcohol produced only a minor shift in the toxin–SNAP-25 dissociation curve, with receptor occupancy remaining above 90% at therapeutic concentrations, and intracellular light-chain degradation accounted for roughly half the variance in recovery timing. This is a modelling study rather than a clinical trial, and its authors disclose extensive industry relationships, so it should be weighted accordingly — but the underlying pharmacology it relies on is not in dispute. Botulinum toxin's light chain persists intracellularly and cleaves SNAP-25 irreversibly; a diluent injected afterwards has no obvious route to undo that.
The defensible summary, and the one worth telling a patient or a colleague: reconstitution with bacteriostatic saline is not known to reduce clinical efficacy, the trials that compared outcomes did not find a difference, and direct stability data on at least one product shows preserved and unpreserved saline behaving equivalently. Benzyl alcohol is neither a threat to the toxin nor an antidote to it.
The second property nobody talks about: multiple-dose handling
The bacteriostatic property is not incidental. It is the reason the product is supplied in a multiple-dose container from which repeated withdrawals may be made.
That has a practical consequence for how a busy room runs. A preservative-free saline ampoule or vial is a single-dose presentation. A bacteriostatic vial is designed for repeated entry with aseptic technique. Practices reconstituting several toxin vials across a clinic day, or splitting a saline vial across multiple reconstitutions, are relying on a property the preservative-free product does not have.
This shades into a related and genuinely contested area: how long reconstituted toxin may be kept, and whether a vial may serve more than one patient. Every US botulinum toxin label describes the vial as single-dose and sets a 24-hour post-reconstitution window — 72 hours for DAXXIFY. Published survey data from dermatologic practice has documented something quite different: Liu and colleagues reported in the Journal of the American Academy of Dermatology in 2012 that 68.6% of surveyed American Society for Dermatologic Surgery members routinely stored reconstituted toxin beyond a week and used vials across multiple patients, with no infections observed in the surveyed cohort.
Two things are true at once. That survey describes what experienced clinicians do. It is not a label permission, it does not override CDC safe-injection guidance, and it is not Empire's recommendation. Practices that depart from label handling own that decision, should have written protocol and aseptic technique to support it, and should be able to explain it.
Contraindications and cautions that actually apply
Neonates. Bacteriostatic saline is contraindicated in neonates because of benzyl alcohol toxicity. The label states this in the contraindications section and repeats it on the carton. Where a sodium chloride solution is required for preparing or diluting medications for neonates, only preservative-free sodium chloride should be used.
Benzyl alcohol sensitivity. Uncommon, but real. A documented hypersensitivity to benzyl alcohol or to preparations containing it is a reason to use preservative-free diluent, and it is worth a line on the intake form rather than a discovery mid-treatment.
Epidural and spinal routes. The label states that parenteral preparations containing benzyl alcohol should not be used in epidural or spinal anaesthetic procedures. Not relevant to facial aesthetics, but relevant to anyone whose practice crosses into interventional pain work.
Volume perspective for the adult patient. The label notes that animal studies of small-volume parenteral preparations containing 0.9% benzyl alcohol indicate an estimated intravenous dose of up to 30 mL may be given to an adult without toxic effects. A full-face neurotoxin treatment delivers on the order of one millilitre of reconstituted solution. The benzyl alcohol exposure in aesthetic practice is trivial in adults; the neonatal contraindication is a paediatric-dosing issue, not an adult-dose one.
Making the choice deliberately
A defensible position for an aesthetic practice looks like this.
Decide which diluent is your standard and write it into protocol, rather than letting it depend on who stocked the drawer. If you use bacteriostatic saline, know and be able to say that it is off-label for this purpose, that the reason is patient comfort, and that the published comparative trials found no efficacy difference. Record the diluent in the treatment note alongside the product, the dose in units and the concentration — consent and documentation practice should reflect the choice you actually made. Screen for benzyl alcohol sensitivity on intake. And keep preservative-free saline available, because some patients and some situations require it.
Dr. Croley's practice of reconstituting with bacteriostatic saline for patient comfort reflects his clinical practice as taught in Empire Medical Training's hands-on curriculum. Technique is learned under supervision; this article is educational and is not a substitute for training.
Injectors who want to work through vial preparation, diluent choice and dosing with live product and supervision can do so in Empire's Complete Botox Training and Cosmetic Neurotoxins Training workshops, or in the broader Complete Facial Aesthetic Training programme.
Related guides in this cluster
Part of Neurotoxin Reconstitution and Dosing.
Clinical GuideOn-Label Reconstitution Across the US Neurotoxins — A Reference Table for InjectorsA complete on-label neurotoxin reconstitution chart for Botox, Dysport, Xeomin, Jeuveau and Daxxify — vial sizes, diluent volumes and u
Clinical GuideWhy a Unit of Botox Is Not a Unit of DysportBotox units vs Dysport units are not the same measure. Units are defined by each manufacturer's own potency assay — here is why no conv
Clinical GuideConcentration as a Clinical Instrument — How Dilution Governs DiffusionNeurotoxin dilution and diffusion, worked as a decision. When to choose a tighter concentration, when to choose a looser field, and wha
Train with Empire
This guide is clinical education. The technique behind it is taught hands-on, on live patients, with faculty beside you.
Explore Botox Training & Certification →Disclaimer
This article reflects the clinical opinions and experience of Dr. Chris Croley, Chief Medical Officer, Empire Medical Training, an independent faculty member contributing to Empire Medical Training's curriculum. The views expressed are the author's own and do not necessarily represent those of Empire Medical Training.
It is professional education, not medical advice, and is no substitute for hands-on training or independent clinical judgment. Licensed clinicians remain responsible for their own patient selection, technique and outcomes, for verifying current product labelling, and for practising within their scope and applicable law. Empire Medical Training accepts no liability for reliance on this content.